Alzheimer's gold rush inspires $565M deal between Chinese pharma powerhouse and little German biotech
The ballooning controversy around Biogen and its Alzheimer’s drug isn’t deterring others from the gold rush — and the search is global.
China’s Simcere is licensing regional rights to a Phase IIb anti-amyloid drug from German biotech Vivoryon Therapeutics and taking the lead on clinical development locally. All told, the pact is valued at up to $565 million, including an undisclosed upfront payment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.